GO:0045746 negative regulation of Notch signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045746 describes any process that stops, prevents, or reduces the frequency, rate or extent of Notch signaling, a conserved cell-cell communication pathway.
• Negative regulation of Notch signaling is essential for developmental patterning, tissue homeostasis, and preventing excessive or ectopic Notch activity.
• Key negative regulators include Numb, which promotes Notch1 degradation, and glycosyltransferases such as XylT that modify Notch receptors.
• Dysregulation of Notch inhibition contributes to cancer progression, including gastric cancer and tumor angiogenesis.
• The pathway is also implicated in immune regulation, demyelinating diseases, and myocardial infarction.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulators in disease contexts.
Description
The Notch signaling pathway is an evolutionarily conserved mechanism that governs cell fate decisions, proliferation, and differentiation across metazoans. Its activity must be tightly controlled; negative regulation of Notch signaling (GO:0045746) encompasses all processes that attenuate or terminate this pathway, ensuring appropriate developmental and homeostatic outcomes. Disruption of these inhibitory mechanisms can lead to pathological conditions ranging from cancer to immune disorders. Understanding the molecular players and regulatory logic of GO:0045746 is therefore critical for both basic developmental biology and translational research. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of the negative regulation of Notch signaling pathway, its key genes, disease relevance, and modern experimental approaches including CRISPR-based models.
negative regulation of Notch signaling pathway At A Glance
| GO ID | GO:0045746 |
|---|---|
| GO term | negative regulation of Notch signaling pathway |
| Ontology | biological_process |
| Synonym | down regulation of Notch signaling pathway; inhibition of Notch signaling pathway; negative regulation of N signaling pathway |
| Major function | Attenuation or termination of Notch signaling to control cell fate, proliferation, and differentiation |
| Key negative regulators | Numb, XylT, GRWD1 (context-dependent), CD51 (via Numb blocking) |
| Associated diseases | Gastric cancer, tumor angiogenesis, acute myocardial infarction, demyelinating diseases |
| Research methods | CRISPR knockout/knock-in, RNA-seq, proteomics, imaging, library screening |
What Is GO:0045746?
GO:0045746, negative regulation of Notch signaling pathway, is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of the Notch signaling pathway. This includes mechanisms such as receptor degradation, inhibition of ligand-receptor interactions, modulation of glycosylation, and transcriptional repression of pathway components.
Why Is negative regulation of Notch signaling pathway Important in Cell Biology?
Negative regulation of Notch signaling is vital because unrestrained Notch activity drives developmental defects and multiple cancers, while excessive inhibition can impair tissue repair and immune responses. Understanding GO:0045746 provides mechanistic insights into how cells balance signaling output and offers therapeutic targets for modulating Notch in disease.
• Prevents ectopic Notch activation during vulval development in C. elegans.
• Controls innate lymphoid cell populations in acute myocardial infarction.
• Regulates differentiation of NG2 cells into oligodendrocytes in demyelinating diseases.
• Modulates tumor angiogenesis through Dll4-Notch signaling.
• Influences gastric cancer stemness via Numb-mediated Notch1 degradation.
• Affects gastric cancer progression through GRWD1-mediated ADAM17 upregulation.
• Mechanically regulated by forces in the cellular microenvironment.
• Glycosylation by xylose transferase negatively regulates Notch in Drosophila.
What Happens During negative regulation of Notch signaling pathway?
Receptor degradation and trafficking
In simple terms: Cells can remove Notch receptors from the surface and send them for destruction, which shuts down signaling.
Numb is a key negative regulator that promotes ubiquitination and degradation of Notch1, thereby reducing Notch signaling output. This mechanism is critical for controlling stemness and differentiation in gastric cancer cells.
Glycosylation-mediated inhibition
In simple terms: Adding sugar molecules to Notch can block its activation.
Xylose transferase adds xylose to Notch, which negatively regulates Notch signaling in Drosophila. This glycosylation event alters receptor-ligand interactions and downstream activation.
Mechanical regulation
In simple terms: Physical forces on cells can change how Notch signaling is turned off.
Mechanical cues from the microenvironment regulate Notch signaling, including its negative regulation, by modulating receptor conformation and ligand availability.
Transcriptional and post-translational control
In simple terms: Cells can reduce the amount of Notch proteins or block their activity after they are made.
GRWD1 overexpression activates Notch signaling via ADAM17 upregulation, implying that negative regulation can be overridden in cancer. Conversely, CD51 blocks Numb-mediated Notch1 degradation, leading to increased Notch activity.
Regulation in immune and neural contexts
In simple terms: Negative regulation of Notch is important for immune cells and brain cells.
Notch signaling regulates innate lymphoid cells in acute myocardial infarction, and its negative regulation may influence inflammatory responses. In demyelinating diseases, Notch signaling controls NG2 cell differentiation into oligodendrocytes, where negative regulation is essential for proper remyelination.
Key Genes Involved in GO:0045746 negative regulation of Notch signaling pathway
The following genes and proteins are central to the negative regulation of Notch signaling, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Numb | Promotes Notch1 degradation | Stemness regulation in gastric cancer |
| XylT | Adds xylose to Notch, inhibiting signaling | Developmental regulation in Drosophila |
| GRWD1 | Activates Notch via ADAM17 upregulation | Gastric cancer progression |
| CD51 | Blocks Numb-mediated Notch1 degradation | Cancer stemness |
| Dll4 | Ligand that activates Notch; its regulation affects angiogenesis | Tumor angiogenesis |
| Notch1 | Receptor subject to negative regulation | Multiple cancers and development |
| ADAM17 | Protease that cleaves Notch; upregulated by GRWD1 | Cancer progression |
| NG2 | Proteoglycan on oligodendrocyte precursor cells | Demyelinating diseases |
| Innate lymphoid cells | Immune cells regulated by Notch | Acute myocardial infarction |
| Mechanical cues | Physical forces modulating Notch | Microenvironment regulation |
| Vulval development genes | Model for Notch negative regulation | C. elegans development |
| Notch signaling components | Core pathway elements | General negative regulation |
How Is negative regulation of Notch signaling pathway Regulated?
Negative regulation of Notch signaling is itself regulated at multiple levels. Mechanical forces from the extracellular matrix can modulate Notch receptor activation and its inhibition. Glycosylation by XylT directly inhibits Notch in Drosophila. In cancer, GRWD1 overexpression activates Notch via ADAM17, effectively counteracting negative regulation. CD51 blocks Numb-mediated Notch1 degradation, thereby reducing negative regulation and promoting stemness. These examples illustrate that negative regulation is a dynamic process integrated with cellular context.
negative regulation of Notch signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRWD1 | Gastric cancer | Knockout or overexpression in gastric cancer cell lines |
| CD51 | Gastric cancer stemness | Knockdown or knockout in cancer stem cells |
| Numb | Gastric cancer | Point mutation to disrupt Notch1 degradation |
| Dll4 | Tumor angiogenesis | Knockout in endothelial cells |
| NG2 | Demyelinating diseases | Knockout in oligodendrocyte precursor cells |
Cancer
Dysregulated negative regulation of Notch signaling contributes to gastric cancer progression. GRWD1 overexpression activates Notch via ADAM17 upregulation, promoting tumor growth. CD51 blocks Numb-mediated Notch1 degradation, enhancing cancer stemness. In tumor angiogenesis, Dll4-Notch signaling is critical, and its negative regulation affects vessel formation.
Cardiovascular disease
Notch signaling regulates innate lymphoid cells in patients with acute myocardial infarction, suggesting that negative regulation of Notch may influence post-infarction inflammation and repair.
Neurological disorders
In demyelinating diseases, Notch signaling controls the differentiation of NG2 cells into oligodendrocytes. Negative regulation of Notch is necessary for proper remyelination, and its dysregulation may contribute to disease pathology.
Developmental disorders
In C. elegans vulval development, negative regulation of Notch signaling by genes such as XylT ensures proper cell fate patterning; disruptions lead to developmental abnormalities.
From negative regulation of Notch signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does Numb negatively regulate Notch1 in gastric cancer? | Numb knockout via CRISPR in gastric cancer cell lines |
| How does XylT inhibit Notch signaling? | XylT overexpression or knockout in Drosophila |
| What is the role of GRWD1 in Notch activation? | GRWD1 overexpression in gastric cancer cells |
| Does CD51 block Numb-mediated Notch1 degradation? | CD51 knockout or knockdown in cancer stem cells |
| How does mechanical force affect Notch negative regulation? | Microfluidic or stretch models with Notch reporters |
| Does Dll4-Notch negative regulation affect angiogenesis? | Endothelial cell knockout of Dll4 or Notch components |
How to Study the negative regulation of Notch signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function phenotypes | Identify negative regulators of Notch |
| RNA-seq | Transcriptional changes | Measure pathway gene expression |
| Proteomics | Protein abundance and modifications | Detect Numb-mediated degradation |
| Imaging | Spatiotemporal signaling dynamics | Visualize Notch inhibition |
| Flow cytometry | Cell surface Notch levels | Quantify receptor downregulation |
| Western blot | Protein expression | Validate knockout or overexpression |
| Luciferase reporter | Notch transcriptional activity | Screen for inhibitors |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify novel negative regulators of Notch signaling by selecting for cells with altered Notch activity.
RNA-seq and transcriptomics
RNA sequencing reveals transcriptional changes in Notch pathway components and negative regulators upon genetic perturbation.
Proteomics and interactomics
Mass spectrometry-based proteomics can map protein interactions and post-translational modifications that mediate Notch inhibition, such as ubiquitination by Numb.
Imaging and reporter assays
Live-cell imaging with Notch reporters allows real-time visualization of negative regulation dynamics in response to mechanical or chemical cues.
How CRISPR Can Be Used to Study GO:0045746 negative regulation of Notch signaling pathway
Knockout
CRISPR knockout of negative regulators such as Numb or XylT can lead to hyperactive Notch signaling, revealing their essential roles in pathway inhibition.
Point Mutation
Introducing point mutations in Notch or its regulators can dissect specific domains required for negative regulation, such as ubiquitination sites on Notch1.
Knock-in
Knock-in of tagged versions of negative regulators (e.g., GFP-Numb) allows live-cell tracking of their localization and dynamics.
Overexpression
Overexpression of negative regulators like XylT or GRWD1 can suppress or activate Notch signaling, respectively, providing gain-of-function insights.
How EDITGENE Supports negative regulation of Notch signaling pathway Research
Researchers studying negative regulation of Notch signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway attenuation or whether its modulation can alter disease phenotypes. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of Notch signaling pathway research.
Frequently Asked Questions About negative regulation of Notch signaling pathway
What is negative regulation of Notch signaling pathway?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of Notch signaling, as defined by GO:0045746.
What genes are involved in negative regulation of Notch signaling?
Key genes include Numb, XylT, CD51, and GRWD1, among others.
How does Numb negatively regulate Notch signaling?
Numb promotes ubiquitination and degradation of Notch1, reducing its signaling output.
What diseases are linked to defective negative regulation of Notch signaling?
Gastric cancer, tumor angiogenesis, acute myocardial infarction, and demyelinating diseases.
How can CRISPR be used to study negative regulation of Notch signaling?
CRISPR knockout, knock-in, point mutation, and overexpression models allow precise manipulation of negative regulators.
What is the role of glycosylation in negative regulation of Notch?
Xylose transferase adds xylose to Notch, which inhibits signaling in Drosophila.
Does mechanical force affect negative regulation of Notch?
Yes, mechanical cues from the microenvironment regulate Notch signaling, including its negative regulation.
What is the connection between Notch and innate lymphoid cells?
Notch signaling regulates innate lymphoid cells in acute myocardial infarction, and its negative regulation may influence immune responses.
How does GRWD1 affect Notch signaling?
GRWD1 overexpression activates Notch via upregulation of ADAM17, counteracting negative regulation.
What experimental models are used to study negative regulation of Notch?
Common models include CRISPR knockout cell lines, Drosophila genetics, and mouse models of cancer and demyelination.
Conclusion
Negative regulation of Notch signaling (GO:0045746) is a critical process that ensures proper developmental and homeostatic control of Notch activity. Its dysregulation is implicated in cancer, cardiovascular disease, and neurological disorders. Advances in CRISPR-based models and high-throughput screening are accelerating the discovery of new negative regulators and therapeutic targets. EDITGENE offers comprehensive services to support these research efforts.
References
- 1. Suarez Rodriguez F et al.. 2023. Mechanical regulation of the Notch signaling pathway.. Curr Opin Cell Biol 85:102244 PMID: 37783031
- 2. Yu H et al.. 2023. Regulation of Notch Signaling Pathway to Innate Lymphoid Cells in Patients with Acute Myocardial Infarction.. Immunol Invest 52(2):241-255 PMID: 36562737
- 3. Lee TV et al.. 2013. Negative regulation of notch signaling by xylose.. PLoS Genet 9(6):e1003547 PMID: 23754965
- 4. Sternberg PW. 2005. Vulval development.. WormBook PMID: 18050418
- 5. Ding H et al.. 2024. GRWD1 Over-Expression Promotes Gastric Cancer Progression by Activating Notch Signaling Pathway via Up-Regulation of ADAM17.. Dig Dis Sci 69(3):821-834 PMID: 38172445
- 6. Peng J et al.. 2025. CD51 promotes gastric cancer stemness via blocking Numb-mediated Notch1 degradation.. Cancer Lett 629:217886 PMID: 40555320
- 7. Liu Z et al.. 2014. Dll4-Notch signaling in regulation of tumor angiogenesis.. J Cancer Res Clin Oncol 140(4):525-36 PMID: 24114288
- 8. Li C et al.. 2022. The Notch Signaling Pathway Regulates Differentiation of NG2 Cells into Oligodendrocytes in Demyelinating Diseases.. Cell Mol Neurobiol 42(7):1-11 PMID: 33826017
